James E Barrett1,2,3, Karin Sundström4,5, Allison Jones3, Iona Evans3, Jiangrong Wang4, Chiara Herzog1, Joakim Dillner4,5, Martin Widschwendter6,7,8. 1. European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Milser Straße 10, 6060, Hall in Tirol, Austria. 2. Research Institute for Biomedical Aging Research, Universität Innsbruck, 6020, Innsbruck, Austria. 3. Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, 74 Huntley Street, London, WC1E 6AU, UK. 4. Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden. 5. Medical Diagnostics Karolinska, Karolinska University Hospital, Stockholm, Sweden. 6. European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Milser Straße 10, 6060, Hall in Tirol, Austria. Martin.Widschwendter@uibk.ac.at. 7. Research Institute for Biomedical Aging Research, Universität Innsbruck, 6020, Innsbruck, Austria. Martin.Widschwendter@uibk.ac.at. 8. Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, 74 Huntley Street, London, WC1E 6AU, UK. Martin.Widschwendter@uibk.ac.at.
Abstract
BACKGROUND: Cervical screening is transitioning from primary cytology to primary human papillomavirus (HPV) testing. HPV testing is highly sensitive but there is currently no high-specificity triage method for colposcopy referral to detect cervical intraepithelial neoplasia grade 3 or above (CIN3+) in women positive for high-risk (hr) HPV subtypes. An objective, automatable test that could accurately perform triage, independently of sample heterogeneity and age, is urgently required. METHODS: We analyzed DNA methylation at ~850,000 CpG sites across the genome in a total of 1254 cervical liquid-based cytology (LBC) samples from cases of screen-detected histologically verified CIN1-3+ (98% hrHPV-positive) and population-based control women free from any cervical disease (100% hrHPV-positive). Samples were provided by a state-of-the-art population-based cohort biobank and consisted of (i) a discovery set of 170 CIN3+ cases and 202 hrHPV-positive/cytology-negative controls; (ii) a diagnostic validation set of 87 CIN3+, 90 CIN2, 166 CIN1, and 111 hrHPV-positive/cytology-negative controls; and (iii) a predictive validation set of 428 cytology-negative samples (418 hrHPV-positive) of which 210 were diagnosed with CIN3+ in the upcoming 1-4 years and 218 remained disease-free. RESULTS: We developed the WID-CIN (Women's cancer risk IDentification-Cervical Intraepithelial Neoplasia) test, a DNA methylation signature consisting of 5000 CpG sites. The receiver operating characteristic area under the curve (AUC) in the independent diagnostic validation set was 0.92 (95% CI 0.88-0.96). At 75% specificity (≤CIN1), the overall sensitivity to detect CIN3+ is 89.7% (83.3-96.1) in all and 92.7% (85.9-99.6) and 65.6% (49.2-82.1) in women aged ≥30 and <30. In hrHPV-positive/cytology-negative samples in the predictive validation set, the WID-CIN detected 54.8% (48.0-61.5) cases developing 1-4 years after sample donation in all ages or 56.9% (47.6-66.2) and 53.5% (43.7-63.2) in ≥30 and <30-year-old women, at a specificity of 75%. CONCLUSIONS: The WID-CIN test identifies the vast majority of hrHPV-positive women with current CIN3+ lesions. In the absence of cytologic abnormalities, a positive WID-CIN test result is likely to indicate a significantly increased risk of developing CIN3+ in the near future.
BACKGROUND: Cervical screening is transitioning from primary cytology to primary human papillomavirus (HPV) testing. HPV testing is highly sensitive but there is currently no high-specificity triage method for colposcopy referral to detect cervical intraepithelial neoplasia grade 3 or above (CIN3+) in women positive for high-risk (hr) HPV subtypes. An objective, automatable test that could accurately perform triage, independently of sample heterogeneity and age, is urgently required. METHODS: We analyzed DNA methylation at ~850,000 CpG sites across the genome in a total of 1254 cervical liquid-based cytology (LBC) samples from cases of screen-detected histologically verified CIN1-3+ (98% hrHPV-positive) and population-based control women free from any cervical disease (100% hrHPV-positive). Samples were provided by a state-of-the-art population-based cohort biobank and consisted of (i) a discovery set of 170 CIN3+ cases and 202 hrHPV-positive/cytology-negative controls; (ii) a diagnostic validation set of 87 CIN3+, 90 CIN2, 166 CIN1, and 111 hrHPV-positive/cytology-negative controls; and (iii) a predictive validation set of 428 cytology-negative samples (418 hrHPV-positive) of which 210 were diagnosed with CIN3+ in the upcoming 1-4 years and 218 remained disease-free. RESULTS: We developed the WID-CIN (Women's cancer risk IDentification-Cervical Intraepithelial Neoplasia) test, a DNA methylation signature consisting of 5000 CpG sites. The receiver operating characteristic area under the curve (AUC) in the independent diagnostic validation set was 0.92 (95% CI 0.88-0.96). At 75% specificity (≤CIN1), the overall sensitivity to detect CIN3+ is 89.7% (83.3-96.1) in all and 92.7% (85.9-99.6) and 65.6% (49.2-82.1) in women aged ≥30 and <30. In hrHPV-positive/cytology-negative samples in the predictive validation set, the WID-CIN detected 54.8% (48.0-61.5) cases developing 1-4 years after sample donation in all ages or 56.9% (47.6-66.2) and 53.5% (43.7-63.2) in ≥30 and <30-year-old women, at a specificity of 75%. CONCLUSIONS: The WID-CIN test identifies the vast majority of hrHPV-positive women with current CIN3+ lesions. In the absence of cytologic abnormalities, a positive WID-CIN test result is likely to indicate a significantly increased risk of developing CIN3+ in the near future.
Authors: Martin J Aryee; Andrew E Jaffe; Hector Corrada-Bravo; Christine Ladd-Acosta; Andrew P Feinberg; Kasper D Hansen; Rafael A Irizarry Journal: Bioinformatics Date: 2014-01-28 Impact factor: 6.937
Authors: Erik J Nelson; Brandy R Maynard; Travis Loux; Jessica Fatla; Rebecca Gordon; Lauren D Arnold Journal: Sex Transm Infect Date: 2016-10-19 Impact factor: 3.519
Authors: Helen Kelly; Yolanda Benavente; Miquel Angel Pavon; Silvia De Sanjose; Philippe Mayaud; Attila Tibor Lorincz Journal: Br J Cancer Date: 2019-10-16 Impact factor: 7.640
Authors: Jiayao Lei; Alexander Ploner; K Miriam Elfström; Jiangrong Wang; Adam Roth; Fang Fang; Karin Sundström; Joakim Dillner; Pär Sparén Journal: N Engl J Med Date: 2020-10-01 Impact factor: 91.245
Authors: Andrew E Teschendorff; Francesco Marabita; Matthias Lechner; Thomas Bartlett; Jesper Tegner; David Gomez-Cabrero; Stephan Beck Journal: Bioinformatics Date: 2012-11-21 Impact factor: 6.937
Authors: Joakim Dillner; Matejka Rebolj; Philippe Birembaut; Karl-Ulrich Petry; Anne Szarewski; Christian Munk; Silvia de Sanjose; Pontus Naucler; Belen Lloveras; Susanne Kjaer; Jack Cuzick; Marjolein van Ballegooijen; Christine Clavel; Thomas Iftner Journal: BMJ Date: 2008-10-13
Authors: Karoliina Tainio; Antonios Athanasiou; Kari A O Tikkinen; Riikka Aaltonen; Jovita Cárdenas; Sivan Glazer-Livson; Maija Jakobsson; Kirsi Joronen; Mari Kiviharju; Karolina Louvanto; Sanna Oksjoki; Riikka Tähtinen; Seppo Virtanen; Pekka Nieminen; Maria Kyrgiou; Ilkka Kalliala Journal: BMJ Date: 2018-02-27
Authors: Jesper Bonde; Arno Floore; Ditte Ejegod; Frederique J Vink; Albertus Hesselink; Peter M van de Ven; Anja Oštrbenk Valenčak; Helle Pedersen; Saskia Doorn; Wim G Quint; Karl Ulrich Petry; Mario Poljak; Grazyna Stanczuk; Kate Cuschieri; Silvia de Sanjosé; Maaike Bleeker; Johannes Berkhof; Chris J L M Meijer; Daniëlle A M Heideman Journal: Int J Cancer Date: 2020-10-21 Impact factor: 7.396